An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy.
An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy.
复制标题
一项观察性研究，检查接受新辅助或辅助化学疗法的乳腺癌患者的代谢综合征成分变化。
DOI：
10.1002/cncr.30104
复制
发表时间：
2016-09-01
期刊：
影响因子：
6.2
通讯作者：
Mortimer JE
中科院分区：
文献类型：
--
作者：
Dieli-Conwright CM;Wong L;Waliany S;Bernstein L;Salehian B;Mortimer JE
作者试图确定化疗对接受早期乳腺癌（新）辅助治疗的绝经前和绝经后女性代谢综合征（MetS）发生的影响。共有86名患有早期（AJCC阶段I-III）乳腺癌的女性没有临床诊断的MetS（定义为MetS的5种成分中的3种），在开始前和完成（新）辅助化疗后1周内前瞻性检测了MetS的5种成分的存在。测量的MetS的5个组成部分是腰围;血压;血糖、甘油三酯和高密度脂蛋白胆固醇的空腹水平。在开始治疗前和完成治疗后，还检查了人体测量学（体重、体脂百分比、脂肪量）、血脂谱（总胆固醇、低密度脂蛋白胆固醇）、葡萄糖代谢（胰岛素、胰岛素抵抗的稳态模型评估、糖化血红蛋白）和炎症（C反应蛋白）。目前的研究包括46名绝经前和40名绝经后妇女。化疗后，所有个体MetS组分和总体MetS评分均显著增加（P<0.01）。体重、体脂百分比、脂肪量、脂质、葡萄糖代谢和炎症也被发现在统计学上显著增加（P<0.01）。12周至18周的化疗似乎在统计学上显著增加了MetS和相关的人体测量学，葡萄糖代谢生物标志物，以及没有预先存在MetS的早期乳腺癌患者的炎症。生活方式干预，如饮食和运动可能是化疗期间使用的预防方法，以减少乳腺癌患者MetS的发生。癌症2016.© 2016作者。出版社：Wiley Periodicals，Inc.代表美国癌症协会Cancer 2016;122：2646-2653.© 2016美国癌症协会。 接受（新）辅助化疗的乳腺癌患者的代谢表现受损，表现为代谢综合征、人体测量学和葡萄糖代谢生物标志物的恶化。生活方式干预，如饮食和运动可能是化疗期间使用的预防方法，以减少乳腺癌患者代谢综合征的发生。
The authors sought to determine the effect of chemotherapy on the development of metabolic syndrome (MetS) in premenopausal and postmenopausal women undergoing (neo)adjuvant therapy for early‐stage breast cancer. A total of 86 women with early‐stage (AJCC stage I‐III) breast cancer who were free from clinically diagnosed MetS (defined as 3 of 5 components of MetS) were prospectively tested for the presence of the 5 components of MetS within 1 week before initiating and after completing (neo)adjuvant chemotherapy. The 5 components of MetS measured were waist circumference; blood pressure; and fasting levels of blood glucose, triglycerides, and high‐density lipoprotein cholesterol. Anthropometrics (body weight, percentage body fat, fat mass), lipid profile (total cholesterol, low‐density lipoprotein cholesterol), glucose metabolism (insulin, homeostatic model assessment of insulin resistance, glycated hemoglobin), and inflammation (C‐reactive protein) also were examined before initiating and after completing treatment. The current study included 46 premenopausal and 40 postmenopausal women. All individual MetS components and the overall MetS score were found to be statistically significantly increased (P<.01) after chemotherapy. Body weight, percentage body fat, fat mass, lipids, glucose metabolism, and inflammation also were found to be statistically significantly increased (P<.01). A 12‐week to 18‐week course of chemotherapy appears to statistically significantly increase MetS and related anthropometrics, biomarkers of glucose metabolism, and inflammation in patients with early‐stage breast cancer with no preexisting MetS. Lifestyle interventions such as diet and exercise may be preventive approaches for use during chemotherapy to reduce the onset of MetS in patients with breast cancer. Cancer 2016. © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. Cancer 2016;122:2646–2653. © 2016 American Cancer Society. Patients with breast cancer who receive (neo)adjuvant chemotherapy experience an impaired metabolic presentation as noted by worsened components of metabolic syndrome, anthropometrics, and biomarkers of glucose metabolism. Lifestyle interventions such as diet and exercise may be preventive approaches for use during chemotherapy to reduce the onset of metabolic syndrome in patients with breast cancer.